Join to View Full Profile
3015 N Ballas RdDes Peres, MO 63131
Phone+1 314-996-5169
Fax+1 314-996-5674
Dr. Mehan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2010 - 2013- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
Loyola University Chicago Stritch School of MedicineClass of 2006
Certifications & Licensure
MO State Medical License 2009 - 2026
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013
Publications & Presentations
PubMed
- 6 citationsRandomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).Michael J Morris, Glenn Heller, David W Hillman, Olivia Bobek, Charles Ryan
Journal of Clinical Oncology. 2023-06-20 - 196 citationsPhase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma...Ramesh K. Ramanathan, Shannon McDonough, Philip A. Philip, Sunil R. Hingorani, Jill Lacy
Journal of Clinical Oncology. 2019-02-28 - 16 citationsPazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion studyDouglas Adkins, Paul Mehan, Jessica Ley, Marilyn J. Siegel, Barry A. Siegel
The Lancet. Oncology. 2018-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
